Personalized cell therapies have transformed cancer treatment for some patients, but they share a common problem: each dose has to be custom-built from that patient’s own cells, a process that can take weeks and cost hundreds of thousands of dollars. A team at UCLA thinks they’ve found a way around that bottleneck, by starting not with mature immune cells, but with stem cells taken from donated cord blood.
Going a Step Deeper Than CAR-T
The therapy
relies on T cell receptor (TCR) engineering, a cousin of the better-known CAR-T
approach. CAR-T cells can only recognize proteins sitting on the outer surface
of a cancer cell. TCR-based cells go further: they can spot fragments of
proteins made inside a tumor cell and later
displayed on its surface like an identifying tag. That distinction matters a
lot for solid tumors, where many of the telltale molecular changes never make
it to the cell’s exterior.
The catch has always been manufacturing. Personalized TCR therapy requires processing each patient’s own cells individually. Ready-made versions built from donor T cells exist too, but they carry a serious risk: graft-versus-host disease, in which the transplanted immune cells attack the recipient’s healthy tissue.
Starting Earlier in the Cell’s Life
Instead of
engineering mature donor T cells, the UCLA team, led by Lili Yang, with
co-first author Yichen (John) Zhu and co-senior author Yanruide (Charlie) Li,
started with blood stem cells pulled from cord blood. These cells haven’t yet
committed to becoming any particular immune cell type. The researchers inserted
a gene for a receptor that recognizes NY-ESO-1, a protein found across many
solid tumor types, and then let the engineered stem cells mature into T cells
in the lab.
Because the receptor is added before the cells differentiate, the resulting T cells don’t carry the random grab-bag of natural receptors that mature donor T cells do, which is exactly what causes graft-versus-host disease in the first place. Every resulting cell, called an AlloESO-T cell, homes in on the same target.
A Second Way to Catch Cancer
Solid tumors are notoriously good at slipping past single-target therapies, some cancer cells simply stop displaying the marker a treatment is designed to find, a phenomenon called antigen escape. To hedge against that, the AlloESO-T cells were also built to carry natural killer cell receptors that respond to general stress signals many tumor cells give off, giving the cells a backup way to identify and kill cancer even if it stops presenting NY-ESO-1.
What Happened in Mice
In mouse models of ovarian cancer and melanoma, a single dose of AlloESO-T cells produced durable tumor control and longer survival — while cells engineered from conventional mature donor T cells only partially controlled tumors and triggered graft-versus-host disease. After infusion, the AlloESO-T cells expanded roughly 100-fold, migrated into tumors, and stayed active for weeks while largely sparing healthy organs, a marked contrast to the donor-derived cells, which built up in the liver and lungs and caused toxicity.
Why Scale Matters
Because stem
cells can be expanded so extensively, the manufacturing math changes
dramatically. The team estimates that a small starting batch of cord blood stem
cells could be turned into trillions of therapeutic cells, enough for thousands
of doses, in about six weeks, at a projected cost of roughly $5,000 per dose.
That’s a steep drop from the six-figure price tags attached to today’s
personalized cell therapies.
The
researchers also frame AlloESO-T as a platform rather than a one-off product:
any validated receptor for a given cancer antigen could, in principle, be built
into the same stem-cell-based system to generate T cells against a different
target. UCLA has already partnered with its Center for Advanced Biotherapies to
manufacture clinical-grade cells for a related program, and hopes to lean on
that same infrastructure to move AlloESO-T toward clinical testing.
It’s worth underlining that these results are preclinical, the therapy has only been tested in mice so far, not in human trials, and hasn’t been evaluated by the FDA. But as a proof of concept for cheaper, faster, off-the-shelf cell therapy against solid tumors, it’s a compelling one. The study was published in Cell Reports Medicine.
Sources
·
UCLA Health press release: Scientists engineer
ready-to-use cancer-fighting T cells for solid tumors
Source: Cord Blood Could Turn Into an Off-the-Shelf Cancer Weapon, UCLA Study Suggests
No comments:
Post a Comment